BIOMAT Database Logo BIOMAT Database Logo

Renal transplantation from living donors mismatched for two HLA haplotypes. 1987

G Sødal, and D Albrechtsen, and K J Berg, and H Bondevik, and I B Brekke, and P Fauchald, and A Jakobsen, and T Talseth, and E Thorsby, and A Flatmark
Department of Surgery, Rikshospitalet, Oslo 1, Norway.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006239 Haplotypes The genetic constitution of individuals with respect to one member of a pair of allelic genes, or sets of genes that are closely linked and tend to be inherited together such as those of the MAJOR HISTOCOMPATIBILITY COMPLEX. Haplotype
D006650 Histocompatibility Testing Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed) Crossmatching, Tissue,HLA Typing,Tissue Typing,Crossmatchings, Tissue,HLA Typings,Histocompatibility Testings,Testing, Histocompatibility,Testings, Histocompatibility,Tissue Crossmatching,Tissue Crossmatchings,Tissue Typings,Typing, HLA,Typing, Tissue,Typings, HLA,Typings, Tissue

Related Publications

G Sødal, and D Albrechtsen, and K J Berg, and H Bondevik, and I B Brekke, and P Fauchald, and A Jakobsen, and T Talseth, and E Thorsby, and A Flatmark
[Mini-transplantation from HLA-mismatched donors].
September 2003, Nihon rinsho. Japanese journal of clinical medicine,
G Sødal, and D Albrechtsen, and K J Berg, and H Bondevik, and I B Brekke, and P Fauchald, and A Jakobsen, and T Talseth, and E Thorsby, and A Flatmark
Cord blood transplantation from HLA-mismatched unrelated donors.
May 2002, Leukemia & lymphoma,
G Sødal, and D Albrechtsen, and K J Berg, and H Bondevik, and I B Brekke, and P Fauchald, and A Jakobsen, and T Talseth, and E Thorsby, and A Flatmark
Significance of HLA matching in renal transplantation from living donors.
December 1996, Transplantation proceedings,
G Sødal, and D Albrechtsen, and K J Berg, and H Bondevik, and I B Brekke, and P Fauchald, and A Jakobsen, and T Talseth, and E Thorsby, and A Flatmark
Donor nonspecific blood transfusions before renal transplantation from haplo-mismatched living related donors.
February 1989, Transplantation proceedings,
G Sødal, and D Albrechtsen, and K J Berg, and H Bondevik, and I B Brekke, and P Fauchald, and A Jakobsen, and T Talseth, and E Thorsby, and A Flatmark
Renal transplantation from living donors.
February 1999, BMJ (Clinical research ed.),
G Sødal, and D Albrechtsen, and K J Berg, and H Bondevik, and I B Brekke, and P Fauchald, and A Jakobsen, and T Talseth, and E Thorsby, and A Flatmark
Renal transplantation from living donors.
May 1988, The Medical journal of Australia,
G Sødal, and D Albrechtsen, and K J Berg, and H Bondevik, and I B Brekke, and P Fauchald, and A Jakobsen, and T Talseth, and E Thorsby, and A Flatmark
Renal transplantation between living-related sibling pairs matched for zero-HLA haplotypes.
January 1989, Transplantation,
G Sødal, and D Albrechtsen, and K J Berg, and H Bondevik, and I B Brekke, and P Fauchald, and A Jakobsen, and T Talseth, and E Thorsby, and A Flatmark
Is transplantation of two HLA DR mismatched living-donor kidneys justifiable?
January 2001, Transplantation proceedings,
G Sødal, and D Albrechtsen, and K J Berg, and H Bondevik, and I B Brekke, and P Fauchald, and A Jakobsen, and T Talseth, and E Thorsby, and A Flatmark
Importance of certain HLA-A,B haplotypes for the survival of renal grafts from living-related donors.
December 1992, Transplantation proceedings,
G Sødal, and D Albrechtsen, and K J Berg, and H Bondevik, and I B Brekke, and P Fauchald, and A Jakobsen, and T Talseth, and E Thorsby, and A Flatmark
The use of HLA-mismatched living related donors for renal transplantation is justified by the highly successful long-term results.
October 1988, Transplantation proceedings,
Copied contents to your clipboard!